Is Asarfi Hospital overvalued or undervalued?

As of 14 November 2025, the valuation grade for Asarfi Hospital has moved from very attractive to attractive. The company is currently considered overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which indicates a potential growth opportunity despite the higher valuation metrics.
In comparison to its peers, Asarfi Hospital's PE ratio is significantly lower than Apollo Hospitals, which stands at 63.77, and Max Healthcare, which is at 89.07. This suggests that while Asarfi Hospital is currently overvalued, it may still offer a more attractive entry point relative to its peers. Notably, the stock has outperformed the Sensex with a year-to-date return of 75.1% compared to the Sensex's 8.22%, reinforcing the narrative of strong performance despite its current valuation status.